Phathom Pharmaceuticals, Inc. Stock Based Compensation

Stock Based Compensation of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Stock Based Compensation growth rates and interactive chart.


Highlights and Quick Summary

  • Stock Based Compensation for the quarter ending September 29, 2021 was $4.42 Million (a 4.3% increase compared to previous quarter)
  • Year-over-year quarterly Stock Based Compensation increased by 85.75%
  • Annual Stock Based Compensation for 2020 was $5.84 Million (a 1338.42% increase from previous year)
  • Annual Stock Based Compensation for 2019 was $406 Thousand (a Infinity% increase from previous year)
  • Twelve month Stock Based Compensation ending September 29, 2021 was $14.9 Million (a 18.79% increase compared to previous quarter)
  • Twelve month trailing Stock Based Compensation increased by 154.33% year-over-year
Trailing Stock Based Compensation for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$14.9 Million $12.5 Million $9.1 Million $5.84 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Stock Based Compensation of Phathom Pharmaceuticals, Inc.

Most recent Stock Based Compensationof PHAT including historical data for past 10 years.

Interactive Chart of Stock Based Compensation of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Stock Based Compensation for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $4.42 $4.24 $3.82
2020 $2.38 $2.07 $0.83 $0.56 $5.84
2019 $0.34 $0.04 $0.03 $0.41
2018 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.